Standout Papers

Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interfer... 1998 2026 2007 2016 1.9k
  1. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus (1998)
    Thierry Poynard, Patrick Marcellin et al. The Lancet
  2. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study (2012)
    Patrick Marcellin, Edward Gane et al. The Lancet
  3. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection (2011)
    Bruce R. Bacon, Stuart C. Gordon et al. New England Journal of Medicine
  4. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C (2004)
    Marianne Ziol, Adriana Handra‐Luca et al. Hepatology
  5. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B (2005)
    George Lau, Teerha Piratvisuth et al. New England Journal of Medicine
  6. Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B (2003)
    Patrick Marcellin, Ting‐Tsung Chang et al. New England Journal of Medicine
  7. Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B (2004)
    Patrick Marcellin, George Lau et al. New England Journal of Medicine
  8. Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B (2003)
    Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos et al. New England Journal of Medicine
  9. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆ (2004)
    Scott Bowden, Stephen Locarnini et al. Gastroenterology
  10. Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years (2006)
    Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos et al. Gastroenterology
  11. Controlled Attenuation Parameter (CAP): A Novel VCTE™ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes (2010)
    M. Sasso, Michel Beaugrand et al. Ultrasound in Medicine & Biology
  12. Liver diseases: A major, neglected global public health problem requiring urgent actions and large‐scale screening (2018)
    Patrick Marcellin, B. Kutala Liver International

Immediate Impact

9 by Nobel laureates 7 from Science/Nature 130 standout
Sub-graph 1 of 14

Citing Papers

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
2025 Standout
New Approaches to Chronic Hepatitis B
2023 Standout
25 intermediate papers

Works of Patrick Marcellin being referenced

Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients
2019
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
2012 Standout
and 31 more

Author Peers

Author Last Decade Papers Cites
Patrick Marcellin 33396 33397 1970 3989 625 37.8k
Mark Sulkowski 21923 20077 1580 6058 396 26.2k
Eugene R. Schiff 22320 21998 1324 3169 361 28.2k
Thomas Berg 19755 19785 1277 3169 715 27.3k
David L. Thomas 21194 20450 1461 4077 287 26.6k
John G. McHutchison 36416 32868 3702 4593 459 42.6k
Mitchell L. Shiffman 27265 27020 2319 2743 269 33.5k
Stuart C. Gordon 18011 16208 1744 2579 328 21.2k
Antonio Craxı̀ 19193 19269 1862 1766 511 25.6k
Thierry Poynard 33163 35335 1773 2807 425 42.7k
K. Rajender Reddy 27667 24323 1731 3834 577 36.3k

All Works

Loading papers...

Rankless by CCL
2026